© Reuters. FILE PHOTO: Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo
(Reuters) – Eli Lilly (NYSE:) and Co said on Friday it will acquire privately held drug developer Versanis for up to $1.93 billion, adding to its portfolio of obesity drugs.
Read the full article here
Unlock the White House Watch newsletter for freeYour guide to what the…
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…
This article was written byFollowMichael Wiggins De Oliveira is an inflection investor.…
Unlock the White House Watch newsletter for freeYour guide to what the…
